A patient with hidradenitis suppurativa (HS) can look better today and still be doing worse over time. That apparent contradiction gets at one of the harder things about treating HS—we see the disease in moments. Whether it’s the inflammatory nodule that brought someone in, an abscess after it’s finally drained, or that painful area now improved, the disease itself is not always operating on that same timetable.

Repeated inflammation can leave something behind. Tunnels form. Scars accumulate. Previously unaffected areas become involved. Pain and drainage begin shaping choices a patient makes, from what they wear, to how they approach the workday or make plans at all. At some point, the clinical question changes from how to settle the current episode to how much of the future course can still be altered.

Recognizing the Window to Intervene

Recent work has applied the concept of a therapeutic “window of opportunity” to the disease, reflecting growing attention to the period in which controlling inflammatory activity may have implications beyond short-term symptom relief. It’s a rather intuitive premise; inflammatory disease may remain modifiable, while established structural damage is much harder to undo. In HS, where recurrent inflammation can ultimately alter the architecture of the skin, the challenge is recognizing that moment.

Severity scores and lesion counts do not tell the whole story. Recurrence in the same areas is telling. So is persistent drainage, escalating pain, new tunnels or scarring, difficult anatomic involvement and disease that continues to return despite repeated courses of conventional treatment. A relatively modest lesion count can coexist with a disease course that is plainly moving in the wrong direction.

That should make us cautious about equating temporary improvement with adequate control. It also changes the way we think about escalation. The therapeutic landscape for moderate-to-severe HS has broadened substantially, and with it the questions clinicians can ask when treatment is not accomplishing enough.

Rather than waiting for a patient to accumulate a certain amount of visible disease, we can consider trajectory: Is inflammation truly controlled? Are flares becoming less frequent? Are new areas becoming involved? Are tunnels developing? Is the disease continuing to dictate the patient's life?

A Broader Therapeutic Landscape

At the same time, our understanding of the inflammatory biology of HS continues to develop. There is no single pathway that explains the disease. Multiple cytokines and signaling networks appear to contribute, which is one reason interest has expanded beyond established extracellular targets to intracellular signaling pathways such as JAK/STAT.

Selective JAK1 inhibition is now among the strategies being investigated in HS. Povorcitinib, an investigational oral selective JAK1 inhibitor, has completed Phase 3 studies in moderate-to-severe disease; its U.S. New Drug Application has been accepted by the FDA and is currently under review.

But an expanding treatment landscape makes the central question more important: what are we actually trying to accomplish when we treat HS?

Relieving pain and controlling active lesions are immediate goals. Preventing the next flare and preserving what has not yet been lost to chronic inflammation and structural change are too. For some patients, the most consequential treatment decision may therefore come before HS looks its worst.